clinical trial · NCT04883528
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Covid19Sacubitril / Valsartan Oral Tablet [Entresto]Placebo
brief summary
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.
started
Aug 6, 2021
primary completion
Jun 13, 2023
completion
Jun 13, 2023
last updated
Jul 3, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol